Abstract

Background:The eradication of Helicobacter plori (HP) is dependent on several bacteriologic and geographic variables. Multiple-drug regimens have been tried in order to eradicate HPi; however, the optimal drug has not yet been found. Material/Methods: In this single-blind, randomized clinical trial, 245 dyspeptic patients with positive rapid urease test's or positive cultures for HP were entered in the study and randomly treated with one of 3 drug regimens A, B, or C for 14 days. Each regimen was administered to 76 patients. Regimen A consisted of orneprazole 20 mg bid + bismuth subcitrate 120 mg 2 tab. bid + metronidazole 250 mg 2 tab. bid + tetracycline 250 mg 2 cap. bid Regmien B consisted of orneprazole 20 mg bid + bismuth subcitrate 120 mg 2 tab. bid + furazolidone 100 mg 2 tab. bid + tetracycline 250 mg 2 cap. bid Regimen C consisted of orneprazole 20 mg bid + bismuth subcitrate 120 mg 2 tab. bid + ciprofloxacin 500 mg bid. A urea breath test was performed 1-2 months after eradication. Results: Of the 245 patients, 228 completed their treatment course. 57 were male and 43 female. Eradication rates were 76.3, 68.4, and 67.1 in groups A, B, and C, respectively (P=0.05). The eradication rate of drug regimen A was greater than B in males (86 vs. 63; p < 0.05), and that of B was greater than C in females (76.7 vs. 53.6; P < 0.05). Conclusions: The therapeutic regimen containing ciprofloxacin is preferable, although all drug regimens were less effective in Iran than in other parts of the world.